GammaCan International, Inc. (OTCBB: GCAN) is a publicly listed biopharmaceutical company focused on the development and commercialization of safe and effective therapies to treat cancer and other disease. We are an Israeli-US company with headquarters in Kiryat Ono, near Tel Aviv, and offices in New York City. Our innovative approach to treating cancer and other diseases is based on using intravenous immunoglobulin (IgG), a safe, non-toxic human plasma-based derived product that can be administered repeatedly. IgG-based therapies have been approved for the treatment of a number of immune deficiencies and autoimmune diseases for over 20 years. We are the first to use IgG to treat cancers.